These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 18541000)

  • 1. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study.
    ; Buller H; Deitchman D; Prins M; Segers A
    J Thromb Haemost; 2008 Aug; 6(8):1313-8. PubMed ID: 18541000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis.
    Mokadem ME; Hassan A; Algaby AZ
    Vascular; 2021 Oct; 29(5):745-750. PubMed ID: 33153401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis.
    Weitz JI; Segers A; Raskob G; Roberts RS; Francis C; Lassen MR; Fuji T; Swaim RM; Lee M; Peters G; DiBattiste PM; Tesfaye F; Strony J
    J Thromb Haemost; 2019 Dec; 17(12):2081-2088. PubMed ID: 31529590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral apixaban for the treatment of acute venous thromboembolism.
    Agnelli G; Buller HR; Cohen A; Curto M; Gallus AS; Johnson M; Masiukiewicz U; Pak R; Thompson J; Raskob GE; Weitz JI;
    N Engl J Med; 2013 Aug; 369(9):799-808. PubMed ID: 23808982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis.
    Barrett YC; Wang J; Knabb R; Mohan P
    Thromb Haemost; 2011 Jan; 105(1):181-9. PubMed ID: 20941459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apixaban for extended treatment of venous thromboembolism.
    Agnelli G; Buller HR; Cohen A; Curto M; Gallus AS; Johnson M; Porcari A; Raskob GE; Weitz JI;
    N Engl J Med; 2013 Feb; 368(8):699-708. PubMed ID: 23216615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.
    Lassen MR; Davidson BL; Gallus A; Pineo G; Ansell J; Deitchman D
    J Thromb Haemost; 2007 Dec; 5(12):2368-75. PubMed ID: 17868430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep Vein Thrombosis and Pulmonary Embolism in the Apixaban Era: From Bench to Bedside.
    Poredos P; Jezovnik MK
    Curr Drug Targets; 2018; 19(6):577-580. PubMed ID: 25981607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer.
    Levine MN; Gu C; Liebman HA; Escalante CP; Solymoss S; Deitchman D; Ramirez L; Julian J
    J Thromb Haemost; 2012 May; 10(5):807-14. PubMed ID: 22409262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.
    Eikelboom JW; O'Donnell M; Yusuf S; Diaz R; Flaker G; Hart R; Hohnloser S; Joyner C; Lawrence J; Pais P; Pogue J; Synhorst D; Connolly SJ
    Am Heart J; 2010 Mar; 159(3):348-353.e1. PubMed ID: 20211294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of upper extremity deep vein thrombosis with apixaban and rivaroxaban.
    Houghton DE; Casanegra AI; Peterson LG; Cochuyt J; Hodge DO; Vlazny D; McBane RD; Froehling D; Wysokinski WE
    Am J Hematol; 2020 Jul; 95(7):817-823. PubMed ID: 32267011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.
    Weitz JI; Bauersachs R; Becker B; Berkowitz SD; Freitas MCS; Lassen MR; Metzig C; Raskob GE
    JAMA; 2020 Jan; 323(2):130-139. PubMed ID: 31935028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
    Agnelli G; Buller HR; Cohen A; Gallus AS; Lee TC; Pak R; Raskob GE; Weitz JI; Yamabe T
    J Thromb Haemost; 2015 Dec; 13(12):2187-91. PubMed ID: 26407753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
    Agnelli G; Becattini C; Meyer G; Muñoz A; Huisman MV; Connors JM; Cohen A; Bauersachs R; Brenner B; Torbicki A; Sueiro MR; Lambert C; Gussoni G; Campanini M; Fontanella A; Vescovo G; Verso M;
    N Engl J Med; 2020 Apr; 382(17):1599-1607. PubMed ID: 32223112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.
    Raskob GE; Gallus AS; Pineo GF; Chen D; Ramirez LM; Wright RT; Lassen MR
    J Bone Joint Surg Br; 2012 Feb; 94(2):257-64. PubMed ID: 22323697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study).
    Nakamura M; Nishikawa M; Komuro I; Kitajima I; Uetsuka Y; Yamagami T; Minamiguchi H; Yoshimatsu R; Tanabe K; Matsuoka N; Kanmuri K; Ogawa H
    Circ J; 2015; 79(6):1230-6. PubMed ID: 25912695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of Extended Treatment Apixaban Versus Low-Molecular-Weight Heparin in Cancer-Associated Venous Thromboembolism.
    Cohen AT; Dhamane AD; Liu X; Singh R; Han S; Stellhorn R; Wang J; Luo X
    J Natl Compr Canc Netw; 2024 Aug; 22(6):397-403. PubMed ID: 39151451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery.
    Imberti D; Gallerani M; Manfredini R
    J Thromb Thrombolysis; 2012 Aug; 34(2):208-13. PubMed ID: 22466929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial.
    Connors JM; Brooks MM; Sciurba FC; Krishnan JA; Bledsoe JR; Kindzelski A; Baucom AL; Kirwan BA; Eng H; Martin D; Zaharris E; Everett B; Castro L; Shapiro NL; Lin JY; Hou PC; Pepine CJ; Handberg E; Haight DO; Wilson JW; Majercik S; Fu Z; Zhong Y; Venugopal V; Beach S; Wisniewski S; Ridker PM;
    JAMA; 2021 Nov; 326(17):1703-1712. PubMed ID: 34633405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial.
    Coppens M; Synhorst D; Eikelboom JW; Yusuf S; Shestakovska O; Connolly SJ
    Eur Heart J; 2014 Jul; 35(28):1856-63. PubMed ID: 24569032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.